Share on LinkedInShare on LinkedIn

ARTICLE · 02 JANUARY 2019

FDA Final Guidance On The BPCIA "Deemed To Be A License" Provision

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

On December 11, 2018, FDA issued final guidance on interpreting the "Deemed to be a License" provision of BPCIA. The guidance provides FDA's interpretation ...

United StatesIntellectual Property

On December 11, 2018, FDA issued final guidance on interpreting the "Deemed to be a License" provision of BPCIA. The guidance provides FDA's interpretation of the provision and its recommendations to sponsors of proposed protein products.

According to the guidance, an approved NDA for a biological product shall be deemed to be a BLA for the product as of the transition date, March 23, 2020. Examples of such products are provided in the guidance's appendix. As of the transition date, the approved NDA will no longer exist, FDA will remove the product from the Orange Book, and FDA will no longer consider any listed patents as relevant for the timing of approving a 505(b)(2) application or ANDA for the product.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from